Since 2019, Predilife has been marketing MammoRisk®, the first breast cancer risk prediction solution in Europe offering women a clear report for personalised screening.
With your doctor, access recommendations adapted to your profile thanks to a health questionnaire (family history, biopsy history, breast density) and a saliva sample allowing us to analyse your “Polygenic Risk Score”.
You will benefit from a personalised screening in order to do everything possible to detect a possible breast cancer as early as possible and thus protect your health. Complete care, reliable results, a unique follow-up, for an essential serenity.
Today, all women from 40 years of age can request a prevention consultation from their doctor and have their breast cancer risk assessment.
Why follow a personalised screening?
- To receive recommendations adapted to your level of risk.
- To confirm that your current screening is the right one.
- To benefit from increased care if you are “at risk”.
- To reassure you, take charge of your health, anticipate in order to act.
Where to receive a prevention consultation?
Screening and prevention, what does the press say?
Predilife is a partner of the European MyPEBS study, in charge of the breast cancer risk assessment platform.
The main objective of the randomised MyPeBS (My Personal Breast Screening) study is to compare the current organised screening measures – based on the single criterion of age (except where women are identified as very high risk) – with a new screening strategy offering a type and frequency of tests based on each woman’s risk level.